Xcout Intel
LYTIX BIOPHARMA
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
Subscribe to see LYTIX BIOPHARMA’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
LYTIX BIOPHARMA at a glance
LYTIX BIOPHARMA is a biotech company headquartered in Norway. Xcout tracks 6 named people at LYTIX BIOPHARMA, including Eric Falcand (Chairman of the Board).
LYTIX BIOPHARMA leadership
- Eric FalcandChairman of the Board
- Brynjar ForbergskogBoard Member
- Claus AnderssonBoard Member
- Darlene Deptula-HicksBoard Member
- Julie Dehaene-PuypeBoard Member
- Marie-Louise FjällskogBoard Member
LYTIX BIOPHARMA competitors
A few of LYTIX BIOPHARMA's closest competitors — see the full list of competitors and alternatives →
Surface Oncology is a clinical-stage biotechnology company focused on developing immunotherapies that target the tumor microenvironment and enhance anti-tumor immune responses. Its programs are intended for cancer patients and are developed for use by oncology physicians and healthcare systems, with potential pharmaceutical partnerships.
Neotx Holdings Ltd. is a biopharmaceutical company that develops cancer therapeutics and immunotherapies. It conducts clinical trials and researches proprietary technologies aimed at advancing cancer treatment.
CVBio is a biotechnology company that develops virus-driven immunotherapies, specifically utilizing engineered oncolytic adenoviruses to target and destroy resistant cancer cells. The company's platform is designed to treat aggressive cancers, including adult and pediatric brain tumors, by selectively infecting tumor cells and eliciting an anti-tumor immune response.
TILT Biotherapeutics is a Finnish biotechnology company developing tumor-targeted immunotherapies, including oncolytic adenoviruses designed to stimulate immune responses against solid tumors. Its therapies are intended for cancer patients and are developed through clinical and pharmaceutical partnerships.
Western Oncolytics Ltd. is a cutting-edge biotechnology and pharmaceutical company headquartered in Pittsburgh, Pennsylvania, focused on developing novel cancer therapies and drug pipelines.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Get LYTIX BIOPHARMA's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on LYTIX BIOPHARMA in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access